FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPE	ROVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	e Responses															
1. Name and Address of Reporting Person * PFEFFER MATTHEW J				2. Issuer Name and Ticker or Trading Symbol SECOND SIGHT MEDICAL PRODUCTS INC [EYES]						C	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner Officer (give title below) Other (specify below)					
	(Last) (First) (Middle) 25134 RYE CANYON LOOP, SUITE 300				3. Date of Earliest Transaction (Month/Day/Year) 06/01/2018											
(Street) VALENCIA, CA 91355			4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
	(City) (State) (Zip)			Table I - Non-Derivative Securities Acqui						Acquire	uired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea					Date, if	(Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		(D) C	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		l [Ownership of B	7. Nature of Indirect Beneficial Ownership	
				(Month/Day/Yea		// Y ear)	Code	le V	Amoui	(A) or (D)	Price	(Instr. 3 and 4)			Direct (D) Or Indirect (I) (Instr. 4)	
Common	Stock		06/01/2018				A		35,533 (1)	3 A	\$ 0 1	18,301])	
Reminder: R	Report on a se	eparate line for each	class of securities be	eneficiall	y owi	ned dire	ectly or	Perso	ns who					on containe		474 (9-02)
Reminder: F	Report on a se	eparate line for each	class of securities be	eneficiall	y owi	ned dire	ectly or	Perso	ns who		quired t	to respond		on containe form displa		474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Transaction	Table II - 3A. Deemed Execution Date, if	Derivat (e.g., pu 4. Transac Code	tive S	Securition alls, was 5. Num of Deriving Securiting Acquires or Dispose	es Acquerrants, ber (vative les (ed (A)	Perso in this a curi uired, Dis options, o	posed of converting tercisable	are not revalid OMB f, or Benefitible securit le and	quired to control (cially O ies) 7. Title of Under Securities	to respond I number. wned and Amount erlying	8. Price of	9. Number o Derivative Securities Beneficially Owned	f 10. Ownersh Form of Derivativ Security:	ip of Indire Benefici Ownersh (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	Derivat (e.g., pu 4. Transac Code	tive S	Securition alls, was 5. Num of Deriving Securiti	es Acquerrants, ber (vative les (d (A)) osed	Person in this a curred, Discoptions, of the Expiration	posed of converting tercisable	are not revalid OMB f, or Benefitible securit le and	quired to control (cially O ies) 7. Title of Under Securities	to respond I number. www.ed and Amount erlying ies 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(f 10. Ownersh Form of Derivativ Security: Direct (I or Indire	ip of Indire Benefici Ownersh (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	Derivat (e.g., pu 4. Transac Code	tive S	5. Num of Deriv Securiti Acquire or Disp of (D) (Instr. 3	es Acquerrants, ber (vative les (d) (A) osed	Person in this a curred, Discoptions, of the Expiration	ons who is form a rently v posed of converti- tercisable Date ay/Year	are not revalid OMB f, or Benefitble securit le and)	quired to control (cially O ies) 7. Title of Under Securities	to respond I number. wned and Amount erlying ies	8. Price of Derivative Security (Instr. 5)	9. Number o Derivative Securities Beneficially Owned Following Reported	f 10. Ownersh Form of Derivativ Security: Direct (I or Indire	ip of Indire Benefici Ownersk (Instr. 4)

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
PFEFFER MATTHEW J 25134 RYE CANYON LOOP, SUITE 300 VALENCIA, CA 91355	X				

Signatures

/s/ John T. Blake, Attorney-in-fact	06/05/2018
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Awarded as compensation for serving on the Board of Directors and its committees.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

POWER OF ATTORNEY

(FOR EXECUTING FORM ID, FORMS 3, 4 AND 5 AND SCHEDULES 13D AND 13G)

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints John Blake and Scott Dunbar, or either of them, signing individually, the undersigned's true and lawful attorneys-in-fact and agents to:

- (i) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the Securities and Exchange Commission of reports required by Section 13(d) and Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or any rules or regulations promulgated thereunder;
- (ii) prepare, execute and file, for and on behalf of the undersigned with respect to holdings of and transactions in securities issued by a company to the undersigned or Second Sight Medical Products, Inc. any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Exchange Act, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and
- (iii) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact in serving in such capacity at the request of the undersigned, are not assuming, nor is Second Sight Medical Products, Inc. assuming, any of the undersigned's responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned's holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-infact or (c) as to any attorney-in-fact individually, until such attorney-in-fact shall no longer be employed by (or ceases to be a Director of) Second Sight Medical Products, Inc.

I hereby declare that any act or thing lawfully done hereunder by the foregoing attorneys-in-fact shall be binding on the undersigned as if done by myself.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 27th day of March, 2018.

/	s/ Matthew Pfeffer
_	Matthew Pfeffer